Production (Stage)
Monopar Therapeutics Inc.
MNPR
$37.11
-$0.905-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.63M | -10.93M | -1.30M | -1.72M | -1.64M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.36M | 4.83M | 199.10K | 334.40K | 328.70K |
| Change in Net Operating Assets | -4.39M | 4.10M | 31.70K | -295.90K | -342.90K |
| Cash from Operations | -5.66M | -2.00M | -1.07M | -1.68M | -1.66M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -325.80K | -14.34M | 985.70K | -2.40K | -983.30K |
| Cash from Investing | -325.80K | -14.34M | 985.70K | -2.40K | -983.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.40K | 56.20M | 0.00 | 100.00 | 3.19M |
| Repurchase of Common Stock | -131.10K | -66.90K | -16.50K | -10.00K | -10.70K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -115.70K | 56.14M | -16.50K | -9.90K | 3.18M |
| Foreign Exchange rate Adjustments | -100.00 | -3.80K | 4.50K | 1.50K | -1.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.10M | 39.80M | -99.80K | -1.69M | 541.50K |